deferiprone has been researched along with Glioma in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas." | 7.83 | Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells. ( Alexiou, GA; Gerogianni, P; Kyritsis, AP; Vartholomatos, E, 2016) |
| " Iron chelators have been shown to have anti-tumor activity; however, deferiprone (DFP), an orally administered iron chelator, has not been previously evaluated in gliomas." | 3.83 | Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells. ( Alexiou, GA; Gerogianni, P; Kyritsis, AP; Vartholomatos, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexiou, GA | 1 |
| Gerogianni, P | 1 |
| Vartholomatos, E | 1 |
| Kyritsis, AP | 1 |
1 other study available for deferiprone and Glioma
| Article | Year |
|---|---|
Deferiprone Enhances Temozolomide Cytotoxicity in Glioma Cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Surv | 2016 |